Modality
siRNA
MOA
KRASG12Di
Target
GIP-R
Pathway
Wnt
DLBCL
Development Pipeline
Preclinical
~May 2014
→ ~Aug 2015
Phase 1
~Nov 2015
→ ~Feb 2017
Phase 2
~May 2017
→ ~Aug 2018
Phase 3
~Nov 2018
→ ~Feb 2020
NDA/BLA
~May 2020
→ ~Aug 2021
Approved
Nov 2021
→ Apr 2031
ApprovedCurrent
NCT08732543
2,505 pts·DLBCL
2025-07→2031-04·Not yet recruiting
NCT06732617
2,133 pts·DLBCL
2021-11→2028-12·Not yet recruiting
4,638 total pts1 indication
CompletedCurrentUpcoming
Catalysts (2)
2028-12-052.7y awayPh3 Readout· DLBCL
2031-04-055.0y awayPh3 Readout· DLBCL
Trial Timeline
Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2
Approved
Not yet…
Approved
Not yet…
Catalysts
Ph3 Readout
2028-12-05 · 2.7y away
DLBCL
Ph3 Readout
2031-04-05 · 5.0y away
DLBCL
Not yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08732543 | Approved | DLBCL | Not yet recr... | 2505 | ORR |
| NCT06732617 | Approved | DLBCL | Not yet recr... | 2133 | ORR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-5094 | Johnson & Johnson | Phase 2/3 | GIP-R | |
| RHH-3592 | Roche | Phase 1/2 | GIP-R | |
| Doxarasimod | Merck & Co | NDA/BLA | FGFR | |
| Zanusertib | AbbVie | Approved | PCSK9 | |
| Pexarelsin | AstraZeneca | Phase 1 | DLL3 | |
| AZN-5978 | AstraZeneca | Phase 2/3 | GIP-R | |
| Ivotuximab | GSK | NDA/BLA | GIP-R | |
| Elrarapivir | Regeneron | Phase 1 | GIP-R | |
| Capifutibatinib | Intra-Cellular | Phase 3 | GIP-R | |
| Terarasimod | Krystal Biotech | Phase 1/2 | PI3Kα |